Drug
Saroglitazar clinical trials
Keep track of what changes. Save the saroglitazar studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
21 studies that test it; most in 2019 (5)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2017 | 3 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 2
Zydus Therapeutics Inc. (18) · Zydus Lifesciences Limited (1) · Asian Institute of Gastroenterology, India (1) · Command Hospital, India (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses saroglitazar is read from its arms, and is right about nine times in ten.
Testing it · 21
- Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA TherapyRecruitingPhase 3Zydus Therapeutics Inc.NCT07424677Written as Saroglitazar Magnesium 1 mg
- Hepatic Impairment With Cirrhosis Due to Cholestatic Liver DiseaseRecruitingPhase 1Zydus Therapeutics Inc.NCT05045482Written as Saroglitazar Magnesium 1 mg
- Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver DiseaseRecruitingPhase 1Zydus Therapeutics Inc.NCT06825559Written as Saroglitazar Magnesium 1 mg
- Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical OutcomesRecruitingPhase 3Zydus Therapeutics Inc.NCT07216235Written as Saroglitazar magnesium 1 mg
- A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With ComorbiditiesRecruitingPhase 4Zydus Lifesciences LimitedNCT05872269Written as Saroglitazar
- Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With FibrosisCompletedPhase 2Zydus Therapeutics Inc.NCT05011305Written as Saroglitazar Magnesium 2 mg
- Saroglitazar Magnesium for Treatment of Primary Biliary CholangitisCompletedPhase 2/3Zydus Therapeutics Inc.NCT05133336Written as Saroglitazar Magnesium 1 mg
- Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary CholangitisActive, not recruitingPhase 3Zydus Therapeutics Inc.NCT06427395Written as Saroglitazar Magnesium 1 mg
- Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)TerminatedPhase 2Zydus Therapeutics Inc.NCT03617263Written as Saroglitazar Magnesium 4 mg Tablet
- Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the USTerminatedPhase 2Zydus Therapeutics Inc.NCT05211284Written as Saroglitazar Magnesium 4 mg
- Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)CompletedPhase 2Zydus Therapeutics Inc.NCT03639623Written as Saroglitazar
- Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic SteatohepatitisCompletedPhase 2Zydus Therapeutics Inc.NCT03061721Written as Saroglitazar magnesium 1 mg
- Saroglitazar Magnesium in the Treatment of Non-Alcoholic SteatohepatitisCompletedPhase 2Zydus Therapeutics Inc.NCT03863574Written as Saroglitazar Magnesium 2mg
- Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic FunctionCompletedPhase 1Zydus Therapeutics Inc.NCT04469920Written as Saroglitazar Magnesium 2 mg
- A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal FunctionCompletedPhase 1Zydus Therapeutics Inc.NCT04446507Written as Saroglitazar magnesium
- Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary CholangitisCompletedPhase 2Zydus Therapeutics Inc.NCT03112681Written as Saroglitazar magnesium 2 mg
- Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dLSuspendedPhase 2Zydus Therapeutics Inc.NCT03097107Written as Saroglitazar Magnesium 1 mg
- An Investigator Initiated Prospective, Four Arms Randomized Comparative Study of Efficacy and Safety of Saroglitazar, Vitamin E and Life Style Modification in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH)Status unknownPhase 3Asian Institute of Gastroenterology, IndiaNCT04193982Written as Saroglitazar
- A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy VolunteersCompletedPhase 1Zydus Therapeutics Inc.NCT04045769Written as Saroglitazar magnesium 4mg
- Study to Evaluate Absorption, Metabolism and Excretion of Single-dose [14C]-Saroglitazar in Healthy Male SubjectsCompletedPhase 1Zydus Therapeutics Inc.NCT04112446Written as Saroglitazar magnesium
Codes
What other systems call saroglitazar · ClinicalTrials.gg INT000010
- MeSH (NLM) C000588741saroglitazarConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) E0YMX3S4JDSAROGLITAZARConfirmed FDA, NLM, Wikidata
- Wikidata Q15269693saroglitazarConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152303SaroglitazarOne source FDA
- DrugBank DB13115One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000588741 | saroglitazar | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | E0YMX3S4JD | SAROGLITAZAR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q15269693 | saroglitazar | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152303 | Saroglitazar | One source FDA |
| DrugBank | DB13115 | — | One source Wikidata |
Also registered as saroglitazar magnesium (UNII K8V5DLS63R).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.